C063P: Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

Catalog No.: C063P | **Product Name:** Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

The cheapest research grade ruplizumab biosimilar (anti-human CD40L/CD40/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by ruplizumab. The research grade ruplizumab biosimilar protein is for research use only.

PRODUCT SPECIFICATIONS

Catalog No.	C063P
Product Name	Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	TNFSF5, CD154, CD40 ligand, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1.
Source/Host	The anti-human CD40L monoclonal antibody ruplizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade ruplizumab biosimilar specifically binds to the human CD40L.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ruplizumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 0.1 EU per 1 μg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade ruplizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade ruplizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is ruplizumab biosimilar research grade? Ruplizumab is a humanized monoclonal antibody that targets CD40 ligand (CD40L / CD154 / TNFSF5). CD40L is expressed primarily on activated T cells and interacts with CD40 on B cells and antigen-presenting cells, playing a critical role in immune activation. By blocking the CD40–CD40L interaction, ruplizumab inhibits T-cell-dependent immune responses and has been investigated for the treatment of autoimmune diseases such as systemic lupus erythematosus and for prevention of transplant rejection. Ruplizumab biosimilar uses the same protein sequences as the therapeutic antibody ruplizumab.